Vanda Pharmaceuticals Inc.
VNDA
$8.81
-$0.48-5.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.72% | 11.12% | 11.78% | 13.37% | 3.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.72% | 11.12% | 11.78% | 13.37% | 3.18% |
| Cost of Revenue | 15.29% | -3.14% | -10.22% | -15.35% | -23.53% |
| Gross Profit | 8.32% | 12.09% | 13.43% | 15.73% | 5.41% |
| SG&A Expenses | 62.52% | 63.87% | 62.42% | 55.72% | 29.70% |
| Depreciation & Amortization | -3.66% | 8.23% | 37.29% | 87.91% | 247.99% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.39% | 45.91% | 41.86% | 35.02% | 15.90% |
| Operating Income | -271.79% | -223.13% | -210.47% | -187.61% | -191.43% |
| Income Before Tax | -504.89% | -492.44% | -610.61% | -1,343.68% | -461.59% |
| Income Tax Expenses | 2,134.99% | -1,251.97% | -1,646.52% | -1,198.17% | -204.99% |
| Earnings from Continuing Operations | -1,066.53% | -413.78% | -512.58% | -805.05% | -853.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,066.53% | -413.78% | -512.58% | -805.05% | -853.29% |
| EBIT | -271.79% | -223.13% | -210.47% | -187.61% | -191.43% |
| EBITDA | -339.80% | -274.92% | -249.92% | -213.00% | -197.28% |
| EPS Basic | -1,049.63% | -406.73% | -504.50% | -794.92% | -835.29% |
| Normalized Basic EPS | -364.52% | -318.02% | -336.42% | -388.19% | -1,131.03% |
| EPS Diluted | -1,021.34% | -390.21% | -474.97% | -723.79% | -1,028.13% |
| Normalized Diluted EPS | -364.52% | -318.02% | -336.42% | -388.19% | -1,112.45% |
| Average Basic Shares Outstanding | 1.36% | 1.36% | 1.32% | 1.33% | 1.32% |
| Average Diluted Shares Outstanding | 1.36% | 1.36% | 1.29% | 1.26% | 1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |